The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), ...

GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

In the first episode of The Deep End Podcast, we meet Jon Nelson, who shares why he volunteered to get brain implants for his relentless depression.

With the cost of untreated mental health conditions on the rise, employees and employers both need a new approach.

H.C. Wainwright analyst Patrick Trucchio revised the price target on Compass Pathways (NASDAQ:CMPS) stock, reducing it to $45 ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Researchers at CU Anschutz are studying the effect of psychedelic mushrooms on patients with treatment-resistant depression.

Neuro Wellness Spa has expanded its reach with the opening of its newest clinic in Brea, California. This marks the 11th ...

An important Senate committee in New Mexico has unanimously advanced legislation to create a program for the medicinal use of ...

Atai Life Sciences (NASDAQ: ATAI) announced after the markets closed on Wednesday that it has priced a registered ...

A trial for psilocybin therapy to treat depression is being opened to Vancouver Island applicants. Psilocybin is a ...

The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), treatment-resistant depression and other mood disorders. But the drug does have ...